Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company whose news flow centers on the development, validation, and commercialization of nucleosome-based blood tests for human and veterinary medicine. Company updates frequently highlight progress across its Nu.Q® platform, including cancer-focused assays, NETosis-related biomarkers, and companion animal diagnostics.
Readers of this VNRX news page can expect coverage of clinical study results, technology milestones, and collaborations. Recent announcements have described breakthrough clinical data for the Nu.Q® Vet Feline assay in detecting lymphoma in cats, positioning it as a potential simple, affordable blood-based liquid biopsy test for feline cancer. Other news has detailed the first commercial sale of Nu.Q® Cancer assays to a major European cancer center for internal certification ahead of routine clinical use in lung cancer management.
VolitionRx also issues news on its role in sepsis and NETosis research. The company has reported inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government-backed real-world program evaluating early detection of sepsis, and has highlighted broader work on NETs biomarkers and point-of-care nucleosome testing. Additional updates cover scientific advances such as its Capture-Seq™ method for enriching ultrashort transcription factor-bound DNA fragments in plasma, which the company positions as a potential foundation for accurate, lower-cost liquid biopsy tests.
Investors and followers will also find announcements on business reviews, licensing and co-marketing agreements with diagnostic companies, capital-raising transactions, and veterinary initiatives such as donations of Nu.Q® Vet Cancer Tests to crisis response dogs. This page aggregates these developments so that readers can track how VolitionRx’s clinical, commercial, and financial activities evolve over time.
VolitionRx (NYSE American: VNRX), a multi-national epigenetics company, has announced a $1.21 million registered direct offering through the sale of common stock and warrants. The offering includes 156,250 shares to company insiders at $0.64 per share, and 1,734,375 shares with accompanying warrants to existing stockholders at the same price.
The warrants allow purchase of up to 1,734,375 additional shares at $0.768 per share, exercisable immediately and expiring in five years. If fully exercised, the warrants could generate an additional $1.3 million. The offering is expected to close around August 5, 2025. Proceeds will support research, product development, clinical studies, and commercialization efforts.
VolitionRx (NYSE AMERICAN: VNRX) reported significant progress in its Nu.Q® Discover program, which has an estimated $200 million annual addressable market. The program now serves over 20 global clients with 14 state-of-the-art immunoassays for epigenetic profiling.
The company's technology was validated in a peer-reviewed publication in the Journal of Biological Chemistry. The largest ongoing project involves a longitudinal Phase 1/2b study expected to complete in 2026, with projected revenue in the hundreds of thousands of dollars.
Volition is exploring co-marketing partnerships and anticipates signing new deals in the coming months, with potential for multi-million dollar partnerships if Nu.Q® assays advance to companion diagnostic use.
VolitionRx (NYSE AMERICAN: VNRX) has achieved a significant breakthrough in medical diagnostics by developing a lateral flow test that can quantify nucleosomes in whole venous blood within minutes. The company conducted a blinded study under the SUMMIT program, testing blood samples from 25 hospital patients in Intensive Care and Emergency Departments.
The new test shows strong correlation with Volition's established Nu.Q® nucleosome assay, enabling rapid detection of immune disruptions associated with conditions like sepsis. Unlike traditional positive/negative tests, this innovation provides quantitative results at the point-of-care, eliminating the need for laboratory processing.
The company plans to advance the SUMMIT program by developing a finger-prick version using capillary blood for broader applications.
VolitionRx (NYSE: VNRX), a multi-national epigenetics company, reported its Q1 2025 financial results and business updates. The company recorded $0.25 million in revenue, up 44% year-over-year, while reducing monthly net cash burn to $1.4 million, a 50% reduction from Q1 2024.
Key highlights include ongoing confidential discussions with over ten companies for Nu.Q® platform commercialization in human diagnostics, with seven potential partners having a combined market value exceeding $600 billion. The company achieved its first revenue from CE-marked Nu.Q® NETs automated product sales in Europe during Q1 2025.
Financial position shows cash and equivalents of $2.6 million as of March 31, 2025, with additional funding of $4.3 million received in Q1 and a subsequent $6.25 million convertible loan note. VolitionRx aims to achieve cash neutrality for full-year 2025.
VolitionRx Limited (NYSE AMERICAN: VNRX) has scheduled its First Quarter 2025 Earnings Conference Call and Business Update for Friday, May 16, 2025, at 8:30 a.m. U.S. Eastern Time. The call will be hosted by Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and Group CEO), and Terig Hughes (Group CFO).
The conference call will discuss Q1 2025 financial and operating results, recent important events, and upcoming milestones. Participants can join via multiple channels including U.S. & Canada toll-free (1-877-407-9716), U.K. toll-free (0 800 756 3429), or international dial-in (1-201-493-6779). A live audio webcast will be available, and a replay will be accessible until May 30, 2025.
VolitionRx Limited (VNRX) has outlined its strategy to become the global leader in NETs (NETosis) testing through a two-pronged approach. First, the company is in confidential licensing discussions with seven international companies (six valued at nearly $600 billion combined) to launch their Nu.Q® NETs test on existing hospital machines. Second, they're leveraging their CE-marked Nu.Q® NETs test, which has already generated its first revenue in Q1 2025 with nine hospital networks across five European countries implementing the test.
The company estimates the Total Addressable Market for Intensive Care Patients testing alone at $1 billion annually, with potential to exceed $10 billion as applications expand. The Nu.Q® NETs test is being evaluated for multiple clinical applications, including sepsis management, cardiac disease, burns, autoimmune diseases, and pregnancy management. The company's strategy mirrors their successful veterinary market approach, aiming for multiple licensing agreements with ongoing revenue and milestone payments.
VolitionRx (NYSE: VNRX) announces significant progress in commercializing its Nu.Q® platform for both human and veterinary diagnostics. CEO Cameron Reynolds reports confidential discussions with over 10 companies, including seven with a combined market value exceeding $600 billion.
The company's focus areas include cancer diagnostics and sepsis monitoring, representing a $25 billion annual market opportunity. Recent achievements include:
- Raised $4.2 million through direct offerings in December 2024 and March 2025
- Advanced lung cancer screening study in Taiwan with 60 patients enrolled
- Secured first revenue for CE-Marked Nu.Q® NETs product in Europe
- Expanded veterinary partnerships with Antech, FujiFilm Vet Systems, and IDEXX
- Achieved first commercial sale of High Throughput Synthetic Sepsis Model
The company aims to secure multiple licensing agreements in human diagnostics during 2025, following their successful veterinary market strategy. Their Nu.Q® platform shows broad applicability in critical disease areas, supported by strong clinical evidence and a substantial patent portfolio.